Nabriva Therapeutics is a commercial-stage biopharmaceutical company based in King of Prussia, PA, dedicated to developing innovative anti-infective agents for the treatment of serious infections.
The company's pipeline research focuses on the development of novel antibiotic candidates, including fosfomycin and pleuromutilins, with the aim of delivering innovative treatments that have the potential to transform the lives of people with infectious diseases.
Generated from the website